Ten years of the Immune Tolerance Network: An integrated clinical research organization

Science Translational Medicine

Volumn 2, Issue 19, 2010, Pages

  Bluestone, Jeffrey A ^a,b   Krensky, Alan M ^a,c   Turka, Laurence A ^a,d   Rotrosen, Daniel ^e   Matthews, Jeffrey B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; FUNDING; HUMAN; IMMUNOLOGICAL TOLERANCE; LEADERSHIP; MEDICAL SOCIETY; NONHUMAN; NOTE; PATENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; RESOURCE MANAGEMENT; TRANSLATIONAL RESEARCH;

ACADEMIC MEDICAL CENTERS; BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; FINANCING, GOVERNMENT; HUMANS; IMMUNE TOLERANCE; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGRAM DEVELOPMENT; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952985811     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000672     Document Type: Note

References (2)

1. L. Lang, High clinical trials attrition rate is boosting drug development costs. Gastroenterology 127, 1026 (2004).
2. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).